Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDP followed by romidepsin for elderly transplant-ineligible relapsed/refractory peripheral T-cell lymphoma
jRCTs031180445Phase 2Completed
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, dexamethasone, cisplatin and romidepsin in peripheral T-cell lymphoma (PTCL). Primary endpoint: 2-year progression-free survival rate. Started Jul 2019; status: completed.
02
Drugs
gemcitabinedexamethasonecisplatinromidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCTs031180445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180445.